Metraipolis › archive › dc_f2e64a7cceb5

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review — Europe PMC PMID:42245690

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42245690
DOI
10.3389/fonc.2026.1851781
License (as archived)
solo-consultazione
Archived
2026-11-01T13:10:48.045Z
SHA-256 of the archived text
a12bc54edb1dd75a3f10c468894c268bee3e9aa444f88d7d81361b0fabccd01e
Stable URL of this page
https://metraipolis.com/documento/dc_f2e64a7cceb5

How to cite

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review — Europe PMC PMID:42245690 — Europe PMC (en), https://europepmc.org/article/MED/42245690 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f2e64a7cceb5 (Metraipolis archive dc_f2e64a7cceb5, sha256 a12bc54edb1dd75a3f10c468894c268bee3e9aa444f88d7d81361b0fabccd01e)
BibTeX
@misc{dcf2e64a7cceb5,
  title = {Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review — Europe PMC PMID:42245690},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42245690},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f2e64a7cceb5; sha256 a12bc54edb1dd75a3f10c468894c268bee3e9aa444f88d7d81361b0fabccd01e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42245690. Agents can read the archived copy with the MCP tool read_document.